Abstract Library

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,

#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin

Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hackeng W, Geisenberger C, de Leng W, Morsink F, Vriens M,

Keywords: Methylation profiling, Neuroendocrine tumor, Machine Learning, Unknown Primary,

#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours

Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sadeh A, Librizzi D, Figiel J, Rodepeter F, Denzer U,

Keywords: Ki-67, prognosis, endoscopic ultrasound, intestinal NET, pancreatic metastases,

#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours

Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sorbye H

Authors: Sorbye H, Meyer L, Mordal K, Myhre S, Thiis-Evensen E,

Keywords: Quality of life, small-intestinal neuroendocrine tumors, patient reported symptoms, coping, somatostatin analogue,

#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors

Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Isiangulova A, Khasanov R,

Keywords: neuroendocrine tumors, somatostatin analogues, target therapy, everolimus, systemic therapy,